genomic co-amplification of tpx2 and aurka with myc ... · genomic co-amplification of tpx2 and...
TRANSCRIPT
Genomic co-amplification of TPX2 and AURKA with MYC cooperatively promote MYC-driven carcinogenesis
Yusuke Takahashi1,3, Paul Sheridan2 ([email protected]), Atsushi Niida2, Genta Sawada1,3, Ryutaro Uchi1, Teppi Shimamura2, Hirofumi Yamamoto3, Yuichiro Doki3, Masaki Mori3, Satoru Miyano2, Koshi Mimori1
1) Department of Surgery, Kyushu University Beppu Hospital 2) Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, University of Tokyo 3) Department of Gastroenterological Surgery, Graduate School of Medicine, Suita
AcknowledgementsThe present study was supported in part by the following grants and foundations; CREST, Japan Science and Technology Agency (JST), the Funding Program for Next Generation World-Leading Research-ers (LS094), and the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research.
AbstractGenomic amplifications of chromosome 8q24 and 20q are an early and central event in tumorigenesis of various human malignant diseases. In the present study we utilize copy number and expression profiles of 148 colorectal cancer cases to demonstrate that 8q24 and 20q copy number were significantly correlated and that the activity of MYC (maps to 8q24) was dependant on the expression levels of TPX2 and AURKA (both map to 20q). In vitro assays, the aberant expression of MYC, TPX2, and AURKA generated more aggressive capabilities of anchorage independ-ent growth to normal fibroblast cells. Furthermore, knockdown of TPX2 or AUR-KA, or treatment with AURKA specific inhibitor (MLN8237) effectively suppresed cell proliferation of MYC-expressing colorectal cancer cells. These findings suggest that genomic co-amplification of 8q24 and 20q cooperatively promotes MYC-driv-en carcinogenesis. What is more, TPX2 and AURKA are ideal therapeutic targets for MYC-driven cancers owing to their both having a synthetic lethal interaction with MYC.
1. Clinical significance of MYC, TPX2, and AURKA expression in colorectal cancer
Kaplan-Meier overall survival curves of the 159 colorectal cancer patients. The overall survival of the high MYC and TPX2/AURKA expression group was significantly poorer than that of the other two groups.
Copy number correlation was analysed on array-CGH data of 148 colorectal cancer cas-es. The copy number of chromosome 8q24 and 20q was positively correlated (red ar-row).
Multiuple regression analysis
For each gene G on chromosome 20q, we performed the multiple regression
MYC_AP = β1MYC + β2XG + ε
where MYC_AP denotes the MYC activity profile, MYC denotes the MYC expression values, and XG denotes the expression val-ues of gene G.
Top ten significant chr 20q genes
Copy number correlation was also ana-lysed on public data (Tumorscape) for 161 colorectal cancer cases. The copy number of chromosome 8q24 and 20q was again posi-tively correlated (red arrow).
P-value plot for the 148 colorectal cancer clinical samples (horizontal axis) and public GEO datasets (vertical axis) from multiple regression analysis of the chromosome 20q genes. The expression levels of TPX2 and AURKA were identified as co-regulators of MYC activity.
Analysis of co-amplification of chromosome 8q24 and 20q on Tumorscape data shows positive correlation in various cancers. Num-bers in the round parentheses indicate the number of case sets of each cancer type.
Balloon plot for the 148 colorectal cancer clinical samples of MYC and TPX2 expression levels; balloon size represents MYC module activity. A similar patter was observed for AURKA.
The proposed mechanism of MYC-driven carcinogenesis in which co-ampli-fication and co-expression of TPX2 and AURKA with MYC promotes carcino-genesis.
Cell viability of colorectal cancer cells treated with AURKA inhibitor MLN8237. HCT-116 (MYC high) cells were more sensitive to MLN8237 at 50nM than DLD-1 (MYC low).
To further examine the dependence of MLN8237 on MYC activity similar assays on ectopic MYC expressing DLD-1 and mock cells were conducted. As expected, DLD-1 cells changed sensitivity to the AURKA inhibitor following up-regulation of MYC.
AURKA is known to regulate cell division by phosphorylating multiple downstream targets in mitotic aparatus and the full activation of correct mitotic localization of AURKA require its interaction with the spindle regulator TPX2. Thus, it is considered that MYC and TPX2/AURKA axis constitute an oncogenic network to promote MYC module activity and that targeting the TPX2/AURKA axis is an effective therapeutic strategy. Although a TPX2 inhibitor is not available, various AURKA inhibitors are commercially available. We applied the AURKA inhibitor MNL8237 (ali-sertib) in the present study on two colorectal cancer cell lines: HCT-116 (MYC high expression), and DLD-1 (MYC low expression). In brief it was found that MNL8237 suppressed cell proliferation more effectively and apoptotic cell death more aggressively increased in MLN8237 treated HCT-116 cells than in DLD-1 cells.
Ask me, if you’re interested, and I will try to talk you through this stuff.
MYC module activity for the colorectal cancer clinical samples was analysed using EEM. The MYC activity profile is partially explained by MYC expression (horizontal bar). We will see below that TPX2 and AURKA account for much of the variation in the MYC activity profile that is left unaccounted for by MYC expression.
Extraction of Expression Modules (EEM)
EEM is an algorithm designed to extract a set of genes, called an expression module, from expression data whose members behave coherently. EEM starts from a seed geneset that is as-sociated with some biological function. IT first tests expression coherence of the seed geneset in the expression dataset. If the coherence is statistically significant, EEM extracts a coherent subset of genes from the geneset as an expression module, and the geometric center of the corresponding expression profiles is referred to as an activity profiles of the expression module.
2. Co-amplification between chromosome 8q24 (MYC maps to) and 20q (TPX2 and AURKA map to) was observed in several cancer types
3. Heatmap of MYC module genes reveals MYC ac-tivity is not entirely explained by MYC expression
6. TPX2 and AURKA as therapeutic targets for MYC-driven colorectal cancer
5. Proliferation of colorectal cancer cells with high MYC expression was more effectively inhibited by knockdown of TPX2 and AURKA
4. TPX2 and AURKA co-regulate MYC activity
Gene Symbol P-value for β2>0CSE1L 9.59E-17TPX2 4.32E-16AURKA 5.80E-16CSTF1 7.22E-12SLMO2 5.96E-11AHCY 1.53E-10UBE2C 5.18E-10PSMA7 5.66E-09MAPRE1 6.62E-09DPM1 1.35E-08
Sur
viva
l pro
babi
lity
years
MYC and TPX2/AURKA: low (n=30)
MYC or TPX2/AURKA: high (n=70)
MYC and TPX2/AURKA: high (n=59)
chr8q24
chr20q
MYC
TPX2&
AURKA
MYC
co-a
mpl
ifica
tion
overexpression
overexpression
up regulation
up re
gulat
ionco-e
xpre
ssio
n
Copy numberGene expressionModule activity
a b c
o
x
x - chr8o - chr20
x
o
o
x
x - chr8o - chr20
x
o
ALL (3
91)
Breast
(243)
Colorectal
(161
)
Glioma (
41)
Hepato
cellul
ar (12
1)
Lung
NSC (734
)
Lung
SC (40)
Medullo
blasto
ma (12
8)
Melano
ma (11
1)
MPD (215
)
Ovaria
n (10
2)
Prostat
e (92
)
Renal
(126)
−log10(p−v
alue
)0
12
34
56
a b c
2.5
3.0
3.5
4.0
3.0 3.5 4.0 4.5 5.0
TPX2 expression
MYC
exp
ress
ion
2.5
3.0
3.5
4.0
3.0 3.5 4.0 4.5 5.0
AURKA expression
MYC
exp
ress
ion
ADA
ADNP
ADRM1
AHCY
ARFGAP1ASIPATP9A
AURKA
B4GALT5BCAS1BCAS4BCL2L1BLCAP
BMP7BPIC20orf108C20orf11C20orf111
C20orf112C20orf177
C20orf20
C20orf24
CASS4 CBFA2T2CD40 CDH22CDH4CEBPB
CHMP4B
COL9A3
CSE1L
CSTF1
CTNNBL1
CTSA
CTSZCYP24A1
DDX27DHX35
DIDO1DLGAP4
DNMT3B
DNTTIP1
DOK5
DPM1
DSN1
DYNLRB1
E2F1
EDEM2EDN3
EIF2S2
EIF6ELMO2EPB41L1
ERGIC3EYA2
FAM83D
FER1L4GDAP1L1GDF5GNAS
GSS
GTPBP5HCKHM13
HNF4AID1ITCHKCNB1
KCNG1 KCNK15KCNQ2KCNS1KIF3B
LAMA5LBP LIME1LOC388796
LSM14B
MAFB
MAPRE1
MMP9
MYBL2
MYL9MYT1
NCOA3NCOA6
NDRG3
NECAB3NFATC2
NFS1
NPEPL1OGFR
OPRL1 OSBPL2PABPC1LPARD6B
PCIF1
PCK1
PCMTD2
PFDN4
PHF20PI3
PIGTPKIGPLAGL2PLTP PMEPA1POFUT1PPDPFPPP1R16BPREX1
PROCR
PRPF6
PSMA7
PTGIS PTK6PTPN1PTPRT PXMP4RALGAPB
RALY
RBL1
RBM38RBM39
REM1
RNF114
RPS21RTEL1SALL4 SAMHD1SCAND1SDC4
SEMG2
SERINC3
SGK2SLC12A5SLC13A3SLC2A10SLC2A4RGSLC9A8SLCO4A1
SLMO2
SLPI SNAI1
SNTA1
SPAG4
SPATA2SPINLW1
SRCSS18L1
STAU1
STK4STMN3
STX16SULF2SYCP2TAF4TCEA2
TCFL5
TFAP2CTGIF2 TGM2
TH1L
TM9SF4TNNC2TOP1TOX2
TP53INP2
TP53RK
TPD52L2
TPX2
TSHZ2
TTPAL
TUBB1
UBE2C
UCKL1
UQCC
VAPBWFDC2
WISP2YTHDF1
YWHAB
ZBP1ZFP64
ZGPATZHX3ZMYND8
ZNF217
ZNF334ZNF335ZNF512B0
5
10
15
20
25
0 5 10 15 20 25-log10(p-value) for the GSE21815 dataset
-log1
0(m
eta
p-va
lue)
for t
he G
EO d
atas
ets
MYC
-tubulin
DLD-
1
HCT1
16a b
-tubulin
TPX2HCT116
-tubulin
TPX2DLD-1
HCT116
Pro
lifer
atio
n re
lativ
e ab
sorb
ance
d
0H 24H 48H 72H
DLD-1
0H 24H 48H 72H
-tubulinAURKA
-tubulinAURKA
HCT116
DLD-1
c
siAU
RKA
-2
siAU
RKA
-1
siN
C
siNC
siTPX
2-1
siTPX
2-2 e HCT116
Pro
lifer
atio
n re
lativ
e ab
sorb
ance
DLD-1
0H 24H 48H 72H0H 24H 48H 72H
AURKA-AURKA-2
MYC
moc
k
DLD-1
MYC TPX2
tubulinAURKA
f
Mock
.0
8q24 20q
DLD-1g
Cop
y nu
mbe
r
h
siNC
siTPX
2-1
siTPX
2-2
TPX2
tubulin
TPX2
tubulin
TPX2-TPX2-2
0H 24H 48H 72H
i
0H 24H 48H 72H
Mock
Mock MYC
TPX2-TPX2-2
!"
Inhi
bitio
n ra
tio o
f pro
lifer
atio
n
siTPX2-1 siTPX2-2
Mock
Mock
!"
siAURKA-2siAURKA-1
Inhi
bitio
n ra
tio o
f pro
lifer
atio
n
0H 24H 48H 72H0H 24H 48H 72H
AURKA-
iAURKA-
tubulin
AURKA
siAU
RKA
-2
siAU
RKA
-1
siN
C
tubulinAURKA
Mock MYC
n.s.
n.s.
P<0.01.
P<0.01.
P<0.01.P<0.01.
j
k l m
Pro
lifer
atio
n re
lativ
e ab
sorb
ance
Pro
lifer
atio
n re
lativ
e ab
sorb
ance
.0
DMSOnMnMnM
0H 24H 48H 72H
.0
DMSOnMnMnM
.0
DMSOnMnMnM
.0
DMSOnMnMnM
DLD-1 mock DLD-1 MYC
0H 24H 48H 72H 0H 24H 48H 72H 0H 24H 48H 72H
HCT-116 DLD-1
viab
ility
ratio
viab
ility
ratio